Not to be given IM or SC. Not an antimicrobial agent. Initial treatment requires observation of patients & extensive laboratory monitoring including cardiac function assessment. Severe myelosuppression. Hematologic toxicity, secondary leukemia, mucositis/stomatitis, tumor-lysis syndrome, early/delayed cardiotoxicity, active or dormant CV disease, prior or concomitant radiotherapy of mediastinal-pericardial area, hypertensive cardiomyopathy, previous therapy w/ anthracyclines or anthracenediones, concomitant use of drugs w/ ability to suppress cardiac contractility or cardiotoxic drugs eg, trastuzumab, high dose cyclophosphamide or 5-fluorouracil. Assess cardiac function prior & during treatment. Perform baseline ECG & periodic follow-up ECG during & immediately after drug therapy. Monitor WBC, blood uric acid, K, Ca phosphate & creatinine levels. Perform blood count, renal & liver function tests prior to each treatment. Inj site effects, extravasation. Avoid use w/ live vaccines. Red urine discolouration for 1-2 days after administration. Intravesical route produce chemical cystitis & bladder constriction symptoms. Severe hepatic impairment. Renal impairment. Women of childbearing potential should use effective contraception. Not to be used during pregnancy. Not recommended during lactation.